Laura Gomez-Acero
Overview
Explore the profile of Laura Gomez-Acero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Acero L, Sanchez-Fernandez N, Subirana P, Ciruela F, Aso E
Pharmacol Biochem Behav
. 2025 Feb;
249:173970.
PMID: 39956277
Behavioral and psychological symptoms of dementia are almost ubiquitous in Alzheimer's disease (AD) but current therapies are not fully effective and safe. In this study, we aim to evaluate the...
2.
Argerich J, Garma L, Lopez-Cano M, Alvarez-Montoya P, Gomez-Acero L, Fernandez-Duenas V, et al.
NPJ Parkinsons Dis
. 2024 Sep;
10(1):172.
PMID: 39256360
The orphan G protein-coupled receptor 37 (GPR37), widely associated with Parkinson's disease (PD), undergoes proteolytic processing under physiological conditions. The N-terminus domain is proteolyzed by a disintegrin and metalloproteinase 10...
3.
Sanchez-Fernandez N, Gomez-Acero L, Castane A, Adell A, Campa L, Bonaventura J, et al.
Neurotherapeutics
. 2024 Sep;
21(5):e00439.
PMID: 39232876
A combination of Δ-tetrahydrocannabinol (Δ-THC) and cannabidiol (CBD) at non-psychoactive doses was previously demonstrated to reduce cognitive decline in APP/PS1 mice, an animal model of Alzheimer's disease (AD). However, the...
4.
Sanchez-Fernandez N, Gomez-Acero L, Sarasola L, Argerich J, Chevigne A, Jacobson K, et al.
Acta Neuropsychiatr
. 2023 Aug;
36(5):320-324.
PMID: 37605951
Objectives: Cannabidiol (CBD) is a phytocannabinoid with great potential in clinical applications. The mechanism(s) of action of CBD require further investigation. Previous studies suggested that adenosine A receptors (ARs) could...
5.
Valle-Leon M, Casajuana-Martin N, Llinas Del Torrent C, Argerich J, Gomez-Acero L, Sahlholm K, et al.
Biomed Pharmacother
. 2023 Feb;
160:114327.
PMID: 36736280
The striatal dopamine D receptor (DR) is generally accepted to be involved in positive symptoms of schizophrenia and is a main target for clinically used antipsychotics. DR are highly expressed...
6.
Martin-Belmonte A, Aguado C, Alfaro-Ruiz R, Moreno-Martinez A, de la Ossa L, Aso E, et al.
Alzheimers Res Ther
. 2022 Sep;
14(1):136.
PMID: 36131327
Alzheimer's disease (AD) is characterized by a reorganization of brain activity determining network hyperexcitability and loss of synaptic plasticity. Precisely, a dysfunction in metabotropic GABA receptor signalling through G protein-gated...
7.
Garro-Martinez E, Vidal R, Adell A, Diaz A, Castro E, Amigo J, et al.
Mol Neurobiol
. 2019 Dec;
57(3):1704-1715.
PMID: 31823197
We previously reported that the inactivation (cKO) or the stabilization (cST) of β-catenin in cells expressing the astrocyte-specific glutamate aspartate transporter (GLAST) is associated with the vulnerability or resilience to...